Jump to ContentJump to Main Navigation
Show Summary Details

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

4 Issues per year


IMPACT FACTOR 2015: 0.742

SCImago Journal Rank (SJR) 2015: 0.204
Source Normalized Impact per Paper (SNIP) 2015: 0.333
Impact per Publication (IPP) 2015: 0.507

Open Access
Online
ISSN
1452-8266
See all formats and pricing
Volume 30, Issue 3 (Jul 2011)

Issues

Copeptin - is There a Role for Another Cardiac Biomarker?

Adriana Unić
  • Clinical Department of Laboratory Diagnostics, Dubrava University Hospital, Zagreb, Croatia
/ Dunja Rogić
  • Clinical Institute of Laboratory Diagnostics, Clinical Hospital Center Zagreb, Zagreb, Croatia
/ Gordana Rajsman
  • Department of Anesthesiology, Reanimatology and Intensive Care, Clinical Hospital Center Zagreb, Zagreb, Croatia
Published Online: 2011-06-21 | DOI: https://doi.org/10.2478/v10011-011-0034-2

Copeptin - is There a Role for Another Cardiac Biomarker?

The discovery and development of new biomarkers continues to be a promising field. Since cardiovascular disease remains the principal cause of death in the developed countries, this is the area in which novel biomarkers have been most extensively evaluated. Arginine vasopressin (AVP or antidiuretic hormone) is one of the key hormones in the human body involved in cardiovascular homeostasis. It has so far escaped introduction into the routine clinical laboratory due to technical difficulties and pre-analytical errors. Copeptin, the C-terminal part of the AVP precursor peptide, was found to be a stable and sensitive surrogate marker for AVP release. During the past years, copeptin measurement has been shown to be of interest in a variety of clinical indications, including cardiovascular diseases such as heart failure, myocardial infarction, and stroke. This review summarizes the recent progress in the diagnostic use of plasma copeptin in cardiovascular diseases.

Kopeptin - Postoji li Uloga za Novi Srčani Biomarker?

Otkriće i razvoj novih biomarkera je područje koje u poslednje dve decenije beleži značajan napredak i zauzima važno mesto na polju kliničke medicine. Kako kardiovaskularne bolesti i dalje predstavljaju glavni uzrok morbiditeta i mortaliteta u razvijenim zemljama, upravo je na tom polju evaluacija novih biomarkera najopsežnija. Arginin-vazopresin (AVP ili antidiuretski hormon) jedan je od ključnih hormona uključenih u održavanje homeostaze u kardiovaskularnom sistemu. Do danas je njegovo određivanje u rutinskoj laboratorijskoj dijagnostici ostalo problematično usled tehničkih poteškoća, ali i brojnih preanalitičkih grešaka. Kopeptin, C-terminalni deo prekursora AVP, stabilan je i osetljiv surogat marker otpuštanja AVP-a. Poslednjih godina, određivanje koncentracije kopeptina dalo je značajan doprinos u dijagnostici i prognozi različitih oboljenja, uključujući i kardiovaskularne bolesti, kao što su srčana slabost, infarkt miokarda i moždani udar. Ovaj pregledni članak prikazuje dosadašnji napredak u dijagnostici i prognozi kardiovaskularnih bolesti zahvaljujući određivanju koncentracije kopeptina kao novog biomarkera.

Keywords: biomarker; copeptin; heart failure; myocardial infarction

Keywords: biomarker; kopeptin; srčana slabost; infarkt miokarda

  • Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010; 48(12): 1703-11. [PubMed] [Web of Science]

  • Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: Update 2010. Am Heart J 2010; 160(4): 583-94.

  • Chan D, Leong LN. Biomarkers in acute myocardial infarction. BMC Medicine 2010: 8: 34. [Web of Science] [Crossref] [PubMed]

  • Morrow DA, De Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007; 115: 949-52. [Web of Science]

  • Chrmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol 2005; 67: 259-84.

  • Chrousos G, Gold PW. The concepts of stress and stress system disorder. Overview of physical and behavioral homeostasis. JAMA 1992; 267(9): 1244-52.

  • Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypotalamic pituitary adrenal axis and stress adaptation. Stress 2004; 7(2): 75-83. [Crossref]

  • Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010; 140: w13101. [Web of Science]

  • Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of Vasopressin. Clin Chem 2006; 52(1): 112-9. [PubMed] [Crossref]

  • Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJZ. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 2008; 12(1): R11. [PubMed] [Crossref]

  • Stoiser B, Mörtl D, Hülsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36(11): 771-8. [Crossref] [PubMed]

  • Khan SQ, Dhillon SO, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Leong L. Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Circulation 2007; 115; 2103-10.

  • Katan M, Müller B, Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Crit Care 2008; 12(2): 117. [PubMed] [Web of Science] [Crossref]

  • Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26(12): 2500-4. [Crossref] [PubMed]

  • Müller B, Morgenthaler NG, Stolz D, Schuetz P, Müller C, Bingisser R, Bergmann A, Tamm M, Christ-Crain M. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37(2): 145-52. [PubMed] [Crossref]

  • Christ-Crain M, Opal SM. Clinical Review: The role of biomarkers in the diagnosis and management of community acquired pneumonia. Crit Care 2010; 14(1): 203. [Crossref]

  • Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Müller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Müller B, Christ-Crain M. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009; 66(6): 799-808. [PubMed] [Crossref]

  • Zweifel C, Katan M, Schuetz P, Siegemund M, Morgenthaler NG, Merlo A, Mueller B, Christ-Crain M. Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurology 2010: 10: 34. [PubMed] [Web of Science] [Crossref]

  • Barreca T, Gandolfo C, Corsini G, Del Sette M, Cataldi A, Rolandi E, Franceschini R. Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis 2001; 11(2): 113-18. [PubMed] [Crossref]

  • Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schwarz S, Hasibeder WR, Friesenecker BE, Dünser MW. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006; 91(11): 4381-6. [PubMed] [Crossref]

  • Reichlin T, et al. Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction. J Am Coll Cardiol 2009; 54: 60-8.

  • Neuhold et al. Comparison of Copeptin, B-Type Natriuretic Peptide, and Amino-Terminal Pro-B-Type Natriuretic Peptide in Patients With Chronic Heart Failure. J Am Coll Cardiol 2008; 52(4): 266-72. [Crossref] [PubMed] [Web of Science]

  • Voors AA, Von Haehling S, Anker SD, Hillegel HL, Struck J, Hartmann O, Bergmann A, Squire I, Van Veldhuisen DJ, Dickstein K. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009; 30(10): 1187-94. [PubMed] [Crossref]

  • Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 2010; 16(1): S37-44. [Crossref]

  • Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, et al. Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes. N Engl J Med 2008; 358: 2107-16. [Web of Science]

  • Christ-Crain M, Stolz D, Jutla S, Couppis O, Muller C, Bingisser R, Schuetz P, Tamm M, Edwards R, Muller B, Grossman AB. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 176: 913-20.

  • Katan M, Morgenthaler NG, Widmer I, Puder J, König C, Müller B, Christ-Crain M. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008; 29(3): 341-6. [PubMed]

  • Robertson GL. The use of vasopressin assays in physiology and pathophysiology. Semin Nephrol 1994; 14: 368-83.

  • Morales DL, Garrido MJ, Madigan JD, Helman DN, Faber J, Williams MR, Landry DW, Oz MC. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003; 75: 926-30.

  • Mellander O, et al. Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community. JAMA 2009; 302(1): 49-57.

About the article


Published Online: 2011-06-21

Published in Print: 2011-07-01


Citation Information: Journal of Medical Biochemistry, ISSN (Online) 1452-8266, ISSN (Print) 1452-8258, DOI: https://doi.org/10.2478/v10011-011-0034-2. Export Citation

This content is open access.

Comments (0)

Please log in or register to comment.
Log in